Yahoo
NasdaqCM - BOATS Real Time Price USD

Vivos Therapeutics, Inc. (VVOS)

0.1727 +0.0041 (+2.43%)
At close: September 2 at 4:00:01 PM EDT
0.1730 +0.0003 (+0.17%)
Overnight: 1:20:50 AM EDT
Chart Range Bar
Loading chart for VVOS
Chart does not reflect overnight price.
  • Previous Close 0.1686
  • Open 0.1576
  • Bid 0.1622 x 400
  • Ask 0.1900 x 500
  • Day's Range 0.1575 - 0.1802
  • 52 Week Range 0.1575 - 4.5700
  • Volume 7,407,164
  • Avg. Volume 11,787,359
  • Market Cap (intraday) 3.474M
  • Beta (5Y Monthly) 6.09
  • PE Ratio (TTM) --
  • EPS (TTM) -1.9300
  • Earnings Date (est.) Nov 16, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 2.12

Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.

www.vivos.com

268

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 9/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

VVOS
91.49%
S&P 500 (^GSPC)
11.99%

1-Year Return

VVOS
95.92%
S&P 500 (^GSPC)
19.50%

3-Year Return

VVOS
97.30%
S&P 500 (^GSPC)
69.77%

5-Year Return

VVOS
99.87%
S&P 500 (^GSPC)
68.98%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 5.14M
Earnings -7.68M
Profit Margin -149.43%

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-5M
0
5M
-180.0%
-160.0%
-140.0%
-120.0%
-100.0%
-80.0%

Analyst Insights

View More

Analyst Price Targets

0.75
2.12 Average
0.1727 Current
3.10 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 6/4/2026
Analyst Ascendiant Capital
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 3 -> 3.1

Statistics

View More

Valuation Measures

Annual
As of 9/1/2026
  • Market Cap

    3.39M

  • Enterprise Value

    15.23M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.11

  • Price/Book (mrq)

    6.86

  • Enterprise Value/Revenue

    0.73

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -121.79%

  • Return on Assets (ttm)

    -56.19%

  • Return on Equity (ttm)

    -8,585.26%

  • Revenue (ttm)

    20.9M

  • Net Income Avi to Common (ttm)

    -25.46M

  • Diluted EPS (ttm)

    -1.9300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.77M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -8.53M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

0.1727 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: